Can a Yogurt-Like drink boost your Gut's good bacteria?

NCT ID NCT07700381

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 14, 2026 · Last updated Aug 28, 2026 · Updated 2 times

Summary

This study investigates whether a fermented dairy product containing three specific Bifidobacterium strains can increase the diversity of gut bacteria in healthy adults aged 45 to 60. Participants consume either the test product or a regular yogurt twice daily for 28 days. Researchers measure changes in the number of distinct Bifidobacterium species in stool samples to see if the probiotic strains survive digestion and enrich the gut microbiome.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a fermented dairy product containing three Bifidobacterium strains
What this could lead to
If successful, this could show that specific probiotic strains survive digestion and increase gut bacteria diversity, pointing toward better digestive health.
What could go wrong
This is a small, early-stage study in healthy people, so results may not apply to those with digestive issues. The effect on actual health outcomes is unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 115 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2026

Expected to finish

Jan 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

45 to 60 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Male and female subjects aged between 45 and 60 years old. 2. BMI between 18.5 kg/m² and 30 kg/m². 3. Subjects who are overtly healthy as determined by the investigator. 4. Able to speak and read in French. 5. Willing and able to collect their faecal samples themselves. 6. Having access to adequate space to store the investigational. 7. Regular bowel movements. 8. Willing to consume the study products twice per day for 28 consecutive days. 9. Willing not to consume any fermented dairy products during the entire study, other than the study products. 10. Willing not to consume any probiotic, prebiotic or synbiotic supplements during the entire study. 11. Willing to limit alcohol consumption during the study. 12. Willing not to smoke tobacco during the study. 13. Willing not to use any soft or hard drug during the study. 14. Signed written informed consent by the participant. 15. Female subjects must either be postmenopausal for at least 12 months or have undergone specific surgical procedures resulting in sterility or they are using one of the medically approved contraceptive methods. 16. Subject is covered by French health insurance. 17. Subject agrees to be registered in the national database of subjects participating in clinical research. 18. Subject is willing and able to complete the electronic Patient Reported Outcomes using their own digital device having access to internet. Exclusion Criteria: 1. Any ongoing metabolic disease, hypertension, inflammatory disease, thyroid disease, allergic conditions requiring chronic systemic medication, psychiatric disorder, gastrointestinal disorder, chronic pain, or neurological disorder diagnosed by a physician. 2. Known with allergy or intolerance to any ingredients or allergens. 3. Pregnancy or breast-feeding at the screening visit or plan for pregnancy during the study. 4. Any antecedents of digestive surgery, or plan for such surgery during the study. 5. Any dental surgery within the last 4 weeks before the screening visit, or plan for dental surgery during the study. 6. Subject who had any surgery or intervention requiring a general anaesthesia in the preceding 4 weeks before the screening visit, or who plans to have one during the study. 7. Unable (or unwilling) to adhere to protocol requirements. 8. Subject with a special diet at the screening visit, or plan for such diet during the study. 9. Major changes in subject's dietary habits ≤ 4 weeks before the screening visit or plan for such major changes during the study including change in vitamin or mineral supplements use, but except for dietary restrictions related to the study. 10. Enhanced diet together with intense physical activity ≤ 4 weeks before the screening visit, plan for such a diet and training during the study, or plan for major changes in physical activity during the study. 11. Use ≤ 8 weeks before the screening visit or plan of use during the study of systemic medication that can affect the gastrointestinal function or plan of use during the study (if needed, incidental use of ≤ 4 tablets of paracetamol, non-steroidal anti-inflammatory drugs (NSAIDs) or aspirin per 2-week period is allowed. 12. Excessive alcohol consumption during the past 6 months before the screening visit. 13. Active smoker, or quit active smoking less than 5 years ago before the screening visit. Not regularly smoking is allowed. 14. Drug abuse based on investigator's judgement. 15. Participation in another study with investigational or marketed products potentially affecting the gut microbiota ≤ 4 weeks before the screening visit or plan for participation in any other intervention study during the study. 16. Living in the same home as others already participating in the study and to concomitantly receive some study products. 17. Subject under guardianship, curatorship, person under judicial protection, family empowerment or future protection mandate. 18. Employees, family members or other relatives of employees of the participating centre or of Danone Global Research \& Innovation Center. 19. Subject's total compensation for participation in clinical studies within the past 12 months, including the compensation expected from the Mellifera study, would exceed the annual ceiling of €6,000.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for A03 - digestive system are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CEN

    RECRUITING

    Dijon, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.